Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The impact of MRD standardized assessment by FDG-PET/CT in patients enrolled in the FORTE trial

In this video, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the value of standardizing measurable residual disease (MRD) assessment in multiple myeloma, highlighting results from an imaging sub-study of the FORTE trial (NCT02203643). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.